| | Author | Year | Patients’ country of origin | Cancer type | No. of patients | Stage/grade | Detection method | Percentage of CIP2A high expression, cutoff value | Median follow- up months | Outcome | Survival analysis method |
| | Böckelman | 2011 | Finland | Tongue cancer | 71 | Grade I-III | IHC | 32/71 (45.1%), | 94.8 | OS | M | | Böckelman | 2011 | Finland | Serous ovarian cancer | 524 | I-IV | IHC | 212/524 (40.5%), | 105.6 | DSS | M | | Dong | 2011 | China | Non-small-cell lung cancer | 90 | I-IV | IHC | 65/90 (72.2%), | NA | OS | M | | Ren | 2011 | China | Renal cell carcinoma | 85 | I-IV | IHC | 36/85 (42.4%), staining intensity: 2-3 | NA | OS | M | | He | 2012 | China | Hepatocellular carcinoma | 136 | I-IV | IHC | 85/136 (62.5%), 2+ to 3+ | NA | OS, DFS | M | | Huang | 2012 | China | Hepatocellular carcinoma | 136 | I-III | RT-PCR | 68/136 (50.0%), above median mRNA expression levels | 39 | OS, RFS | M | | Sung | 2013 | China (Taiwan) | Lung adenocarcinoma | 98 | I-III | RT-PCR | 49/98 (50.0%), median value of mRNA expression levels in lung tumors | 21.5 | OS | M | | Wiegering | 2013 | Germany | Colon cancer | 104 | I-IV | RT-PCR | NA, above median mRNA expression levels | NA | OS | M | | Xue | 2013 | China | Bladder urothelial cell carcinoma | 117 | Ta, T1-T4 | IHC | 85/117 (72.6%), + to +++ | 57.1 | OS | M | | Yu | 2013 | China | Breast cancer | 164 | Grade I-III | IHC | 58/164 (35.4%), 1+ or 2+ | NA | DSS | M | | Liu | 2014 | China | Nasopharyngeal carcinoma | 280 | I-IV | IHC | 184/280 (65.7%), ROC curves | 63.6 | OS, DFS | M | | Chen | 2015 | China (Taiwan) | Colorectal cancer | 220 | I-IV | IHC | 91/220 (41.4%), | NA | OS | M | | Tang | 2015 | China | Clear cell renal cell carcinoma | 131 | T1-T4 | IHC | 88/131 (67.2%), | NA | OS, DFS | M | | Wang | 2017 | China | Cervical cancer | 127 | I-IV | IHC | NA, + to +++ | NA | OS, DFS | U | | Xu | 2017 | China | Gallbladder carcinoma | 65 | I-IV | IHC | 42/65 (64.6%), moderate or strong, 5-100% positive cells | NA | OS | M |
|
|
